Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Table 1 Global Response Assessment Scale Number Response Grading (%) Outcome 1 Significantly worse 0 Failure of the therapy 2 Somewhat worse 1 to 25 Failure of the therapy 3 Unchanged (neither worse nor better) 26 to 50 Failure of the therapy 4 Somewhat improved 51 to 75 Successful therapy 5 Significantly improved 76 to 100 Successful therapy Inclusion criteria This study included patients with moderate to severe interstitial cystitis who had participated in the experimental trial conducted in January 2023 at the UroGyn Specialists of Florida clinic using the nonFDA-approved BPC-157 peptide
Nature Medicine asks leading researchers to name their top clinical trial for 2025, from gene therapies for prion disease and sickle-cell disease to digital tools for cancer and mental health
Our team does not recommend this practice
Today is the most dangerous time it has ever been in the history of peptides
US$ 23.45
US$ 26.38
US$ 28.87
US$ 26.74